NCT06253273

Brief Summary

Fibromyalgia is a chronic syndrome that causes fatigue, sleep disorders and generalized chronic pain in different parts of the body. This pathology is more prevalent in women and is generally not attributed to any specific cause. This observational study aims to describe some important and health-related factors in patients with fibromyalgia. Participants will have to fill out questionnaires related to sleep, anxiety, impact of the disease and sarcopenia index, and will then take tests related to grip strength for the upper limbs and dynamometry in the lower limbs. We will also employ the use of ultrasound to evaluate architectural measurements. Last but not least, we cannot forget the pain measurements that are so necessary in this study population.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 12, 2024

Completed
9 months until next milestone

Study Start

First participant enrolled

October 31, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 3, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 3, 2025

Completed
Last Updated

May 6, 2025

Status Verified

May 1, 2025

Enrollment Period

5 months

First QC Date

February 2, 2024

Last Update Submit

May 5, 2025

Conditions

Outcome Measures

Primary Outcomes (13)

  • Algometer

    Algometer points: Using an algometer, the pain threshold at each tender point is measured in kg/cm. The higher the value obtained, the less pain the subject has.

    baseline

  • VAS

    Visual Analogic Scale: this self-referenced scale ranges from 0 to 10 where 0 is no pain at all and 10 indicates the worst possible pain endured. The higher the score, the greater the pain

    baseline

  • Circometry

    Contour measurements: The contour of the segment selected for the study will be measured using a tape measure. It is measured in centimeters. the greater the number of centimeters, the greater the diameter and therefore the worse the condition or greater the liquid retention of the subject.

    baseline

  • Dynamometer

    upper limb grip strength: this measuring tool measures upper limb grip strength. the higher the value, the better the subject's state of strength

    baseline

  • Iso-pull

    lower limb strength: this measuring tool measures the strength of lower limbs. the higher the value, the better the subject's state of strength.

    baseline

  • Chair test

    number of squats for 30 seconds: this test consists of seeing how many squats can be done in the test time. The greater the number of squats, the better the subject will be.

    baseline

  • Timed up and go

    balance test: The Timed Up and Go Test is an easy-to-use test to assess the risk of falls.The shorter the test time, the lower the risk of falling.

    baseline

  • anthropometric measurements

    anthropometric measurements with the uso of the Tanita

    baseline

  • muscular architectural stockings

    taking architectural muscle averages using an ultrasound scanner

    baseline

  • Pittsburgh

    sleep quality questionnaire: This test has values from 0 to 21 points maximum. It is interpreted that the higher the score, the worse the quality of sleep.

    baseline

  • FIQ

    fibromyalgia impact questionnaire: The total FIQ score is between 0-100 as each of the items has a score of 0-10 once adapted. Thus, 0 represents the highest functional capacity and quality of life and 100 the worst state.

    baseline

  • SARC-F

    questionnaire to measure sarcopenia risk: The SARC-F is a quick and easy instrument for detecting the risk of sarcopenia, which asks the degree of difficulty an older adult has in performing 4 functional activities. A score greater than 4 indicates risk of sarcopenia.

    baseline

  • HADS

    to evaluate emotional distress in patients with different chronic conditions, assessing cognitive and behavioral symptoms of anxiety and depression. The HADS is composed of two subscales: Depression and Anxiety, each with seven items. The score of each subscale can vary between 0 and 21, since each item presents four response options, ranging from absence/minimal presence = 0, to maximum presence = 3.

    baseline

Secondary Outcomes (1)

  • socio-demographic variables

    baseline

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with fibromyalgia belonging to the Asocación Afinsyfacro de Móstoles. All men and women of the Association who meet the inclusion and exclusion criteria may participate.

You may qualify if:

  • Diagnosed with FM
  • aged between 18 and 75 years
  • agree to participate and sign the informed consent.

You may not qualify if:

  • who do not have recent surgeries
  • patients with reduced mobility
  • adequate level of comprehension to be able to answer the questionnaires that will be provided in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Camilo José Cela

Madrid, 28692, Spain

Location

MeSH Terms

Conditions

FibromyalgiaSarcopenia

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesMuscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Officials

  • Edurne Úbeda D'ocasar

    Associate Professor

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 2, 2024

First Posted

February 12, 2024

Study Start

October 31, 2024

Primary Completion

April 3, 2025

Study Completion

May 3, 2025

Last Updated

May 6, 2025

Record last verified: 2025-05

Locations